Supplementary Figure 7 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 59K, Kaplan-Meier estimates for time-to-progression in the entire treated population (A) and by treatment cohort (B). Kaplan-Meier estimates for overall survival in the entire treated population (C) and by treatment cohort (D).
Authors: F. Stephen Hodi, Donald Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada, Wanyong Zeng, Anita Giobbie-Hurder, Michael B. Atkins, Nageatte Ibrahim, Philip Friedlander, Keith T. Flaherty, George F. Murphy, Scott Rodig, Elsa F. Velazquez, Martin C. Mihm, Sara Russell, Pamela J. DiPiro, Jeffrey T. Yap, Nikhil Ramaiya, Annick D. Van den Abbeele, Maria Gargano, David McDermott
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362552328